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Brief Definit ive Report
Vaccines prevent many infectious diseases. How-
ever, significant challenges remain to develop 
effective and safe vaccines against important dis-
eases such as HIV, malaria, and tuberculosis 
(Plotkin, 2008; Germain, 2010). Most effective 
vaccines are live attenuated variants of the patho-
gens, but for many pathogens, live attenuated vac-
cines have not been successfully developed or are 
not considered safe in humans. Therefore, there 
is renewed interest in the identification of vac-
cine adjuvants that can potentiate the immuno-
genicity of subunit vaccines to prevent viral 
infections and mimic the intact pathogen.
An important mechanism for adjuvant ac-
tion is to activate innate immunity, thereby 
leading to adaptive immunity (Pulendran and 
Ahmed, 2006; Reed et al., 2009; Coffman 
et al., 2010). Agonists for defined pattern rec-
ognition receptors (PRRs), such as Toll-like 
receptors (TLRs), induce innate immunity and 
are a potential new class of adjuvants (Beutler, 
2004; Kawai and Akira, 2010). Synthetic double-
stranded RNA, polyinosinic:polycytidylic acid 
(poly IC), and its more RNase-resistant ana-
logue stabilized with poly-L-lysine (poly ICLC) 
and available for investigation in humans, are 
superior vaccine adjuvants in mice and in non-
human primates (Longhi et al., 2009; Stahl- 
Hennig et al., 2009). The double-stranded RNA is 
a pathogen-associated molecular pattern and 
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Adjuvants are critical for the success of vaccines. Agonists of microbial pattern recognition 
receptors (PRRs) are promising new adjuvant candidates. A mechanism through which 
adjuvants enhance immune responses is to stimulate innate immunity. We studied the 
innate immune response in humans to synthetic double-stranded RNA (polyinosinic:poly-
cytidylic acid [poly IC] stabilized with poly-l-lysine [poly ICLC]), an agonist for toll-like 
receptor (TLR) 3, and the cytosolic RNA helicase MDA-5. Transcriptional analysis of blood 
samples from eight volunteers, after subcutaneous administration of poly ICLC, showed up-
regulation of genes involved in multiple innate immune pathways in all subjects, including 
interferon (IFN) and inflammasome signaling. Blocking type I IFN receptor ex vivo signifi-
cantly dampened the response to poly IC. Comparative transcriptional analysis showed that 
several innate immune pathways were similarly induced in volunteers immunized with the 
highly efficacious yellow fever vaccine. Therefore, a chemically defined PRR agonist like 
poly ICLC can be a reliable and authentic microbial mimic for inducing innate immune 
responses in humans.
© 2011 Caskey et al. This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommer-
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For example, gene expression profiling 
of mouse DCs in response to differ-
ent PRR ligands in vitro showed two 
distinct transcriptional programs: a 
TLR2-like inflammatory response, 
which was induced by PAM3CSK4, 
and a TLR3/MDA5-like antiviral 
response, induced by poly IC, which 
was enriched for IFN-regulatory fac-
tors and for viral- and IFN-responsive 
genes (Amit et al., 2009). Analysis 
of global gene expression changes in 
human PBMCs showed that poly 
IC elicits transcriptional changes that 
are similar to changes after acute viral 
infection. At 3 h, poly IC induced 
changes in genes related to TLR3 sig-
naling, NF-B–dependent pathway, 
and IFN-stimulated pathway, whereas later on, at 24 h, gene 
expression changes were mostly cell-mediated immune re-
sponses involving activation of cell adhesion, cell mobility, and 
phagocytosis (Huang, et al., 2006). These ex vivo signatures 
have provided insights into the mechanism whereby poly IC 
and other PRR ligands perturb the immune system. Yet it is 
not clear if the in vivo innate response to synthetic microbial 
agonists in any species is reliable and is an authentic mimic to a 
microbial vaccine, which is an assumption to the use of these 
agonists as microbial adjuvants.
In this paper, we have gained a systems-wide appreciation 
of the innate immune responses induced in the blood of 
healthy volunteers after s.c. injection of poly ICLC. We find 
that poly ICLC is a reliable inducer of many arms of innate 
immunity in humans and that many of the triggered path-
ways mimic what is seen with YF17D, a successful live atten-
uated viral vaccine.
RESULTS AND DISCUSSION
Poly ICLC injected s.c. is tolerated in healthy volunteers
Preclinical studies in mice showed that s.c. administration 
of poly ICLC in combination with DC-targeted vaccines, a 
vaccine platform which is being developed in our laboratory, 
was superior to the i.m. route in inducing adaptive immune 
responses (unpublished data). To determine if human sub-
jects tolerate poly ICLC administered s.c., because prior 
studies have mainly used the i.m. route (Rosenfeld et al., 
activates innate immunity (Alexopoulou et al., 2001). Both 
poly IC and poly ICLC are recognized by the cytosolic RNA 
helicase MDA-5 and by endosomal TLR3 (Meylan and 
Tschopp, 2006). A major mechanism underlying the strong 
adjuvant function of poly IC in mice is that it is superior at 
inducing systemic type I IFN (Longhi et al., 2009), which has 
many immune stimulatory roles for both T and B lympho-
cytes (Kolumam et al., 2005; Le Bon et al., 2006) and DCs 
(Le Bon et al., 2001; Longhi et al., 2009). Although poly IC 
and poly ICLC have been used for immunotherapy of cancer 
(Morse et al., 2011; Okada et al., 2011), antigen-specific 
responses are variable and it is not yet clear if humans exhibit 
a reliable innate response to poly ICLC.
Gene expression profiling has been successfully used to 
provide a systems-wide appreciation of the early, presumably 
innate molecular signatures to the yellow fever vaccine (YFV) 
YF17D in healthy volunteers. These results revealed an inte-
grated innate response that includes the complement system, 
inflammasomes, and IFNs. This is followed by a broad poly-
functional and persistent adaptive immune response (Gaucher 
et al., 2008; Querec et al., 2009). Querec et al. (2006) re-
ported that the YF17D vaccine activated many TLRs in vitro 
and surmised that multiple PRRs were required for the 
activity of powerful microbial vaccines.
Similarly, systems biology can be used to study the mecha-
nism whereby specific PRR ligands act as vaccine adjuvants 
and exert differential control of innate immune responses. 
Figure 1. s.c. poly ICLC induces transient 
local and systemic reactogenicity. (a) Typi-
cal local erythematosus skin reaction in the 
area of poly ICLC s.c. administration (repre-
sentative subject). (b and c) Frequency of local 
(pain/tenderness at injection site, erythema, 
and induration; b) and systemic (fever, head-
ache, myalgia, and malaise; c) adverse events 
in the first week after poly ICLC (n = 8) or 
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young healthy volunteers, poly ICLC was generally safe with 
tolerable side effects when administered as a single dose of 
1.6 mg s.c. In our ongoing studies in which 1.6 mg poly ICLC is 
being used as a vaccine adjuvant, the reactogenicity was simi-
lar after s.c. injections at 0, 1, and 3 mo (unpublished data).
Poly ICLC reliably induces innate immunity with regulation 
of many IFN-regulated genes
To assess the global innate response to poly ICLC, transcrip-
tional profiling was performed on whole blood samples, col-
lected just before poly ICLC or placebo administration (day 0) 
and at multiple time points thereafter (6 and 12 h and 1, 2, 3, 
7, 14, and 28 d). RNA was extracted, amplified, and hybrid-
ized onto Illumina Expression BeadChips for analysis as pre-
viously described (Gaucher et al., 2008). Multidimensional 
scaling (MDS) and principal component analysis (PCA) 
showed similar gene expression responses to poly ICLC among 
2010; Okada et al., 2011), a total of 12 volunteers were en-
rolled. Eight were randomly assigned to receive a single dose 
of 1.6 mg poly ICLC, a dose which has often been used in 
prior phase I studies, and four to receive placebo (sterile sa-
line; Table S1 and Fig. S1). No treatment-related, grade 4, 
or serious adverse events were reported. Nonetheless, volun-
teers receiving poly ICLC developed erythema and indura-
tion at the site of injection (Fig. 1 A), something which had 
not previously been reported in phase I studies of poly ICLC. 
We tested poly ICLC s.c., which might explain the higher 
frequency of local adverse events. Systemic reactogenicity 
included transient flu-like symptoms, such as malaise, head-
ache, fever, and chills, which were generally mild to moderate 
in severity (Fig. 1, B and C). In addition, there were no clini-
cally significant changes in complete blood cell counts and 
serum chemistries, including liver function tests, 3 and 7 d 
after poly ICLC administration. Thus, in this small cohort of 
Figure 2. Poly ICLC reliably induces IFN signaling in healthy volunteers. (a) Heat map representation of the normalized expression values. Genes 
shown are the top 50 differentially expressed at day 1 (FC > 2 at 5% FDR), the group-level peak time point (poly ICLC n = 8 or placebo n = 4). Each volun-
teer who received poly ICLC (horizontal rows) is represented at the volunteer-specific peak time (right labels), as in Fig. S2. IRGs are highlighted in red.  
*, genes discussed in the text. (b) Heat map representation of the between-subject correlation of the expression values for IRGs at subject-specific peak 
times after poly ICLC administration. The color gradient extends from pink, representing perfect correlation (or a correlation distance r of 0, i.e., 1  r = 0),  
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inflammasome-associated genes (Guarda and So, 2010), for 
example, IL-1, IL1RN, CASP1, and CASP5 (Fig. 3 B), 
where inflammasomes are macromolecular complexes in-
volved in the recognition of danger-associated molecular pat-
terns (Lamkanfi and Dixit, 2009) and in the establishment 
of adaptive immunity to influenza virus infection (Ichinohe 
et al., 2009) and protective responses to mycobacterial spe-
cies and C. albicans (Harris et al., 2010). Poly ICLC induced 
the expression of TNFSF13B (BAFF), which triggers Ig class 
switching in human mucosal B cells (Xu et al., 2008) and 
binds TNFRSF17, a B cell growth factor which predicts 
antibody responses after YF17D vaccination (Querec et al., 
2009). Poly ICLC also increased the expression of components 
of the complement system (C1QB, C3AR1, and SERP-
ING1; Fig. 3 A and Table S2), as well as the expression of 
EIF2AK2 (an EIF2AK4 homologue also known as protein 
kinase RNA-activated, PKR), which regulates protein syn-
thesis by phosphorylating eIF2 during viral infections and is 
also part of the integrated stress response (García et al., 2006). 
C1QB and EIF2AK4 have been shown to be predictors of 
CD8+ T cell responses to the YF17D vaccine (Querec et al., 
2009). Thus, poly ICLC not only induced the IFN signaling 
pathway but also up-regulated gene expression of other com-
ponents of major effector pathways of innate immunity (in-
flammasomes, complement, and IFNs).
Validation of the transcriptional profiling
To validate the gene expression findings, we performed real-
time PCR using the OpenArray Real-Time PCR Platform 
on 20 selected IRGs from Fig. 2 and samples collected at base-
line from volunteers receiving poly ICLC or placebo and 
from days 1 and 7 after poly ICLC. The OpenArray data con-
firmed the highly integrated up-regulation of IRGs by poly 
ICLC at day 1 and high correlation (mean r = 0.81) with the 
corresponding microarray gene expression (Fig. S3).
In addition, we measured the plasma concentrations of 
IFNs and the IFN-–induced chemokine CXCL10. Signifi-
cant differences in concentrations (P < 0.001) between poly 
ICLC and placebo groups were observed at days 1–3 and 
levels returned to baseline at day 7 (Fig. 4 A).
To obtain further validation for type-I IFN signaling in-
duced by poly ICLC in vivo, freshly isolated PBMCs from 
healthy volunteers were cultured with 10 µg/ml IFN- re-
ceptor (IFNAR) blocking mAb or control mAb for 1 h, and 
then poly IC (parent dsRNA) at 50 µg/ml was added to the 
cell culture. We first determined the kinetics of the in vitro 
effects of poly IC on PBMCs. Cells were stimulated with 
50 µg/ml poly IC and collected at 1, 3, 6, 12, 18, and 24 h. 
STAT1 phosphorylation was detected by flow cytometry at 
6 h and at later time points (unpublished data). We estimated 
that the peak gene regulation would occur earlier after direct 
in vitro stimulation of PBMCs with poly IC (12 h) than the 
peak regulation in vivo (24 h). Gene expression analysis re-
vealed that 104 genes were regulated after 6 h of poly IC 
in vitro and 238 genes after 13 h in comparison with unstimu-
lated cells. Gene regulation was defined by FC > 2 at 5% FDR. 
volunteers, with a peak response at day 1 for five out of eight 
individuals, at 12 h for the remaining three, and a return to 
baseline at day 7 for all individuals (Fig. S2). Differential ex-
pression analysis between poly ICLC and placebo groups at 
each time point resulted in 31, 212, and 52 genes showing 
more than a twofold change at 5% false discovery rate (FDR) 
for 12 h, day 1, and day 2, respectively (Table S2). No sig-
nificant differential expression was detected in the placebo 
group relative to the day 0 baseline, even at a very permissive 
FDR (>80%).
Importantly, the expression profiles of individual subjects 
after poly ICLC administration were comparable, both in 
quantity and quality, as illustrated by a heat map of the top 50 
responsive genes (Fig. 2 A). As a further measure of the reli-
ability of the response among healthy volunteers, there was a 
high degree of correlation in expression levels of IFN- 
regulated genes (IRGs) between the subjects after poly ICLC 
administration (Fig. 2 B).
TLR-associated genes (TLR7 and TLR4), other genes 
involved in viral recognition (DDX58 and IFIH1), and 
transcription factor genes (IRF7, IRF5, and IRF1) were up-
regulated by poly ICLC, all features of an IFN response lead-
ing to activation of transcription factors STAT1, STAT2, and 
STAT3. Many of the top regulated genes (92 out of 212 genes 
with fold change [FC] >2 at 5% FDR) by poly ICLC were 
IRGs (Waddell et al., 2010; IRGs listed in Table S3). Poly 
ICLC induced a broad array of IRGs, both genes associated 
with control of replication of several important animal and 
human viruses (IRF1, RIG-I, MDA-5, and IFITM3) and 
genes recently associated with enhanced replication of certain 
viruses in vitro (ADAR and LY6E; Schoggins et al., 2011).
Also, total PBMC counts and frequencies of different 
blood cell subsets were not significantly regulated by poly 
ICLC (unpublished data). Therefore, the observed transcrip-
tional changes in PBMCs were not a result of redistribution 
of different cell subsets but rather of a rapid and reliable in-
duction of gene expression.
Poly ICLC induces many specific genes associated  
with different innate pathways
The gene-by-gene analysis approach identifies individual genes 
that exhibit differences between the poly ICLC and placebo 
groups. To detect molecular signatures that are included within 
a co-expressed or co-regulated set of genes, we performed ca-
nonical pathway analysis using Ingenuity Pathway Analysis 
software. We tested whether a co-regulated set of genes (path-
way) was enriched in the list of genes that were significantly 
regulated by poly ICLC at day 1. Many pathways for innate 
immunity were induced. In addition to IFN signaling, poly 
ICLC stimulated other canonical innate pathways such as 
NF-B signaling, DC maturation, and antigen presentation 
(Fig. 3 A, red blocks for up-regulated genes; and Table S4).
To further describe the scope of the innate pathways in-
duced by poly ICLC, we analyzed the expression of selected 
genes from the regulated canonical pathways. We noted that in 
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Figure 3. Poly ICLC induces multiple genes of innate immunity including inflammasome components. (a) Each column is an up-regulated ca-
nonical pathway for innate immunity (Ingenuity software); each row represents an up-regulated (red) or down-regulated (blue) gene included in one or 
more regulated pathways. The over-representation test was performed using Fisher’s Exact Test, and the significance, displayed on the right, is achieved 
for P < 0.05 (log(p) > 1.3). *, genes discussed in the text. CPRR, cytosolic PRR; PRRR, PRR recognition. (b) Network analysis of inflammasome gene sig-
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In addition, the kinetics of gene regulation between the 
in vitro and in vivo systems might differ.
We then analyzed the effects of IFNAR blocking on gene 
modulation induced by poly IC in vitro. This blockade led to 
an obvious dampening of genes that responded to poly IC. 
Among the 207 genes most affected by poly IC (FC > 2, 
FDR 5%), 97/207 were described as IRGs (Fig. 4 C), and 
83/207 (or 48/83 IRGs) had their response to poly IC 
strongly affected by IFNAR blockade. These results demon-
strated that IRGs are among the top regulated genes induced 
by poly ICLC both in vitro and in vivo.
A defined innate agonist mimics an attenuated  
live viral vaccine
To compare poly ICLC, which is considered to be a mimic of 
viral double-stranded RNA and is known to interact with 
TLR-3 and MDA-5, with a live viral replication-competent 
vaccine, we analyzed the gene expression data in this study to 
We therefore chose to focus our analyses on gene expres-
sion changes after 13 h of poly IC in the presence of IFNAR 
blocking Ab or control Ab.
We then compared the transcriptional profiles of PBMCs 
stimulated with poly IC in vitro (13 h), in the absence of 
IFNAR blockade, to those induced in whole blood after 
in vivo poly ICLC (Fig. 4 B). We focused our comparison 
on the top regulated genes (FC > 2 at 5% FDR) by dsRNA 
in vivo or in vitro and found that 106 were commonly regu-
lated by both in vivo poly ICLC and in vitro poly IC. As ex-
pected, 66 of these commonly regulated genes are known 
IRGs (Table S5). The discordance in gene regulation for the 
other top regulated genes (106 unique to in vivo poly ICLC 
and 101 to in vitro poly IC) may be accounted for by the fact 
that in vivo poly ICLC acts not only on hematopoietic but 
also on nonhematopoietic cells, the main source of type I IFN 
secretion after poly IC in a mouse model (Longhi et al., 2009), 
whereas the in vitro analysis was performed on purified PBMCs. 
Figure 4. Validation of the transcriptional profiling on PBMCs. (a) Poly ICLC induced systemic secretion of IFNs. Plasma concentrations of IFN-, 
IFN-, and CXCL10 at time points after poly ICLC (blue, n = 8) or placebo (red, n = 4) were analyzed by two-way ANOVA. Error bars represent the standard 
error of the mean concentrations. Poly ICLC effects were significant at days 1–3 (*, P < 0.001). (b and c) PBMCs from four donors were stimulated with  
50 µg/ml poly IC for 13 h plus 10 µg/ml IFNAR antibody or isotype control antibody. RNA was extracted for transcriptional analysis. (b) Differential gene 
expression in blood 1 d after in vivo poly ICLC (x axis, n = 8) was compared with differential gene expression in PBMCs after 13 h of poly IC stimulation  
in vitro (y axis, n = 4). Genes falling on the identity line (dark gray) are equally regulated in both systems. A loss curve (dashed blue) is used to infer the local 
trend between the two systems. IRGs are in red. Text labels are added to points for genes with FC > 2 at 5% FDR in at least one comparison. (c) Log2(FC) 
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humans, and currently approved adjuvants do not always 
induce the desired immune response against specific patho-
gens, especially T cell immune responses. We had reported 
that double-stranded RNAs—poly IC and its analogue poly 
ICLC—are superior adjuvants for T cell immunity in animal 
models (Longhi et al., 2009; Stahl-Hennig et al., 2009). To 
help identify and develop adjuvants that are safe for humans, it 
is important to define the innate response to synthetic ligands 
for microbial innate receptors, like poly ICLC for TLR3 and 
MDA-5, in healthy subjects and to compare this response to 
complex microbial vaccines that contain intrinsic adjuvants.
Our results highlight the feasibility of performing such 
research in humans. They also demonstrate the value of using 
systems biology, as it is the only approach that allows the si-
multaneous identification of integrated immune pathways 
that can lead to protection and a thorough comparison of the 
innate response to different adjuvants.
Our study was designed to compare activation of innate 
immune pathways after YF17D (Gaucher et al., 2008; Querec 
et al., 2009) to the immune modulation after poly ICLC. In 
addition to the reliability of the response of human subjects to 
this adjuvant, we found extensive overlap in transcriptional 
profiles, as the top regulated innate immune pathways were 
shared between the attenuated viral vaccine YF17D and the 
prior datasets from volunteers immunized with YF17D vac-
cine (Gaucher et al., 2008). The comparison was performed at 
both the individual gene and the gene set levels. Both poly 
ICLC and YF17D induced a large transcriptional response in 
blood, but the response to poly ICLC was faster and involved 
more genes (212 genes 1 d after poly ICLC and 78 genes 7 d 
after YF17D with FC > 2 at 5% FDR). Using Ingenuity Path-
way Analysis, we found that a large number of similar tran-
scriptional and signal transduction canonical pathways were 
up-regulated at the peak time points, day 1 after poly ICLC 
administration and day 7 after the viral vaccine (Fig. 5 B). 
Pathways induced by poly ICLC at day 1, depicted in Fig. 3 A, 
were similar and shared many identical genes with the path-
ways induced by YF-17D (Table S6). As expected, some 
immune-related pathways were uniquely regulated by YF-17D 
vaccine, such as IL-1 signaling and protein ubiquitination 
among others. This difference in regulation is likely a result of 
the fact that YFV can signal through TLRs 2, 7, and 9 (Querec 
et al., 2006), and it has been demonstrated that signaling 
through different TLRs leads to regulation of a common core 
of genes, but genes that are more specific to the pathogen-
sensing pathway are also triggered (Amit et al., 2009).
Only two vaccine adjuvants (alum and MPL-A) are ap-
proved in the United States for prophylactic vaccination in 
Figure 5. Poly ICLC activated similar 
innate immune pathways as YF17D.  
(a) Differentially expressed genes (DEGs) after 
poly ICLC (n = 8, versus placebos; n = 4, at 
same time points) or YF17D (versus day 0,  
n = 15; Gaucher et al., 2008) at several time 
points after administration. The threshold of 
differential expression is set at FDR 5%, with 
either FC > 2 (solid line) or FC > 1.3 (dashed 
line). Peak transcriptional changes are shown 
after poly ICLC (212 DEGs, day 1) and YF17D 
(78 DEGs, day 7). (b) Heat map showing  
statistically significant canonical pathways 
(Ingenuity Pathway Analysis Software) com-
monly regulated by poly ICLC and YF17D at 
least at four different time points. Columns 
represent time points after either poly ICLC or 
YF17D. Rows represent significantly regulated 
canonical pathways. Heat map colors repre-
sent the ratio of regulated genes/pathway 
genes after poly ICLC or YF17D (pathways not 
overrepresented are dark blue). Maximum 
pathway modulation similarity was obtained 
between poly ICLC at day 1 and YF17D at day 7. 
Pathways were significantly regulated at 7 of 
14 different time points analyzed (green) and 
at 6, 5, and 4 time points in red, blue, and 
black, respectively. The overrepresentation 
test was performed using Fisher’s Exact  
Test. Statistical significance was achieved  
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whereas the blocking effect was evaluated using the interaction term (de-
fined as the difference between the last two differences). For the comparison 
with YFV, the differences calculated were between each time point and day 0. 
The expected proportions of false positives (FDR) were estimated from the 
unadjusted p-value using the Benjamini and Hochberg method (Benjamini 
and Hochberg, 1995). The microarray data are available through the Na-
tional Center for Biotechnology Information Gene Expression Omnibus 
(GEO) under accession no. GSE32862.
OpenArray real-time PCR. 1 µg of total RNA was reverse transcribed 
using the SuperScript VILO cDNA synthesis kit (Invitrogen) with random 
primers. The cDNA was analyzed in duplicate on an OpenArray NT Cycler 
(BioTrove) using TaqMan Real-Time PCR plates (Applied Biosystems) 
preloaded with primer pairs (see Fig. S3 for TaqMan gene expression assay 
identifiers). cDNA samples were loaded into the plates using an OpenArray 
AccuFill instrument (Applied Biosystems) according to the manufacturer’s 
protocols. Each sub-array was loaded with 2.5 µl 2× GeneAmp Fast PCR 
Master Mix (Applied Biosystems), 1 µl 5× TaqMan OpenArray Remix (Ap-
plied Biosystems), 0.3 µl RNase-free water, and 1.2 µl cDNA. The thermal 
cycling protocol was to manufacturer defaults. PCR data were analyzed by 
DataAssist v3.0 (Applied Biosystems) using the CT method. Values were 
normalized by the mean of three housekeeping genes.
Pathway analysis. Ingenuity Pathway Analysis software (Ingenuity Sys-
tems) was used to identify canonical signaling pathways regulated by poly 
ICLC or YF17D (published microarray dataset in Gaucher et al., 2008; 
GEO accession no. GSE13699). Canonical pathway analysis identified the 
pathways from the Ingenuity Pathway Analysis library of canonical pathways 
that were most significant to the dataset. Illumina Probe IDs were imported 
into the Ingenuity software and mapped to the Gene Symbol from Ingenuity 
database. Genes that had a nonadjusted p-value <0.05 at each time point 
after poly ICLC administration (6 and 12 h and 1, 2, 3, 7, 14, and 28 d) or 
YF17D immunization (3, 7, 10, 14, 28, and 60 d) and were associated with 
a canonical pathway in Ingenuity’s Knowledge Base were used for pathway 
analysis. The significance of the association between the dataset and the ca-
nonical pathway was measured in two ways: (1) A ratio of the number of 
genes from the dataset that map to the pathway divided by the total number 
of genes that map to the canonical pathway was displayed; (2) over- 
representation Fisher’s exact test was used to calculate a p-value determining 
the probability that the association between the genes in the dataset and the 
canonical pathway is explained by chance alone. The pathways were ranked 
by log p-value. This score was used as the cutoff for identifying canonical 
pathways significantly (P < 0.05) affected by poly ICLC or YF17D.
IFN gene analysis. IRGs were selected using the IFN-–, IFN-–, IFN-–, 
and IFN-–induced gene lists from human peripheral blood cells published 
by Waddell et al. (2010). We supplemented this list with a query consisting 
of 46 IRGs (Table S3) chosen from our own transcriptional database of 
innate immune IFN responses with additional annotation supplied by the 
Genecards V3 public database (http://www.genecards.org) and the National 
Center for Biotechnology Information Biosystems Database (http://www 
.ncbi.nlm.nih.gov/biosystems).
Phenotyping of blood cell populations. Freshly isolated PBMCs 
were isolated by density gradient centrifugation. Absolute PBMC counts were 
calculated by an automated cell counter (Vi-Cell XR), and PBMCs were 
then cryopreserved in FBS plus 10% DMSO. Frozen PBMCs collected at 
baseline and 1 and 2 d after poly ICLC or placebo administration were rap-
idly thawed at 37°C. 2 × 106 cells were stained in 20 µl PBS 2% FBS accord-
ing to standard protocols. The following antibodies were used to identify 
peripheral blood DCs, monocytes, and lymphoid cells in whole PBMCs: 
CD3 (clone S4.1), CD19 (clone SJ25-C1), CD56 (clone MEM-188), CD14 
(clone Tük4), CD16 (clone 3G8), CD11c (clone 3.9), and CD123 (clone 
AC145). Dead cells were excluded using LIVE/DEAD stain kit (Invitro-
gen). Flow cytometry was performed on an LSRII cytometer (BD), and data 
synthetic double-stranded RNA poly ICLC. These results 
were unexpected because it has been reported in vitro that 
YF17D signals a large number of TLRs (Querec et al., 2006). 
Our findings underscore the fact that a synthetic dsRNA to 
just MDA-5 and TLR3 is able to mimic the early effects of a 
replication-competent and protective vaccine in vivo. Poly 
ICLC is therefore a true viral mimic, and these features of in-
nate immunity need to be evaluated with other new adjuvants 
that are ready for investigational study in humans.
MATERIALS AND METHODS
Study design and objectives. The study was conducted at the Rocke-
feller University Hospital in New York City. This study was approved by 
the Institutional Review Board of The Rockefeller University Hospital. In-
dividual participants in this study provided written informed consent after 
appropriate review, discussion, and counseling by the clinical study team. 
The study was conducted in compliance with the International Conference 
on Harmonization Good Clinical Practice (ICH-GCP) guidelines and regis-
tered on www.clinicaltrials.gov (NCT01012700). Healthy men and women 
aged 18–60 yr were eligible for participation. Exclusion criteria included 
chronic medical conditions, clinically significant abnormal laboratory param-
eters, infection with HIV or Hepatitis B or C virus, and recent receipt of a 
live-attenuated vaccine or blood transfusion.
The study design is summarized in Fig. S1. This study was randomized, 
double blinded, and placebo controlled. The randomization schedule was 
prepared by the Rockefeller University Hospital Pharmacy using a web-
based program (http://www.randomization.com/). Subjects were random-
ized to either 1.6 mg poly ICLC or placebo (sterile saline) in a 2:1 ratio, 
administered s.c. Dose levels were based on safety data from previous trials 
(Rosenfeld et al., 2010). 12 subjects were enrolled. Safety and tolerability of 
poly ICLC or placebo in each cohort were monitored. Adverse events were 
graded according to the Toxicity Grading Scale for Healthy Adult and Ado-
lescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. After re-
ceipt of the study drug or placebo, subjects were followed for 28 d.
Microarray analysis. Blood was collected from each volunteer in PAXgene 
Blood RNA tubes (BD) for whole-blood RNA isolation at baseline (day 0) and 
at 6 and 12 h and 1, 2, 3, 7, 14, and 28 d after poly ICLC or placebo administra-
tion. In brief, RNA was extracted using PAXgene Blood RNA kits (QIA-
GEN) according to the manufacturer’s protocol. Total RNA was checked for 
quantity and quality using a NanoDrop 2000c spectrophotometer (Thermo 
Fisher Scientific) and Experion automated electrophoresis system (Bio-Rad 
Laboratories). Only RNA samples with a 28S/18S ratio >1.5 were processed 
for array analysis. 500 ng of total RNA was amplified using the Illumina Total-
Prep RNA amplification kits (Applied Biosystems) as recommended by manu-
facturer. 750 ng of the biotinylated cRNA was hybridized onto HumanRef-8 
Expression BeadChips v3 (Illumina) at 58°C for 20 h and quantified using an 
iScan System (Illumina) and GenomeStudio software (Illumina).
Analysis of the GenomeStudio output data was conducted using the R 
statistical language (R Development Core Team) and various software pack-
ages from Bioconductor, an open source project for the analysis and compre-
hension of high-throughput genomic data (Gentleman et al., 2004). First, 
arrays displaying unusually low median intensity, low variability, or low cor-
relation relative to the bulk of the arrays were discarded from the rest of the 
analysis. Quantile normalization was applied, followed by a log2 transforma-
tion and batch effect subtraction using the ComBat procedure (Johnson 
et al., 2007). The LIMMA package (Bioconductor; Smyth, 2004) was used to 
fit a linear model to each probe and to perform a (moderated) Student’s t test 
on various differences of interest. For the poly ICLC in vivo experiment, the 
differences calculated were between the poly ICLC and placebo groups, 
separately at each time point. For the in vitro IFNAR-blockade experiment, 
the differences calculated were between PBMCs stimulated with poly IC 
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were analyzed with FlowJo (Tree Star). Total PBMC counts and relative 
frequencies of blood cell subsets between poly ICLC and placebo groups 
were compared using likelihood ratio tests. Statistical significance was 
achieved with p-values <0.05.
Cytokine secretion assays. Plasma samples collected at baseline, 6 h, and 1, 
2, 3, and 7 d after poly ICLC or placebo injection were stored frozen until 
analysis for cytokine production. Plasma concentrations of IFN-, IL-1, 
IL-12p70, IL-6, IL-8, IL-2, IL-10, GM-CSF, and TNF were measured with 
a proinflammatory multiplex kit by Meso Scale Discovery (MSD), according 
to manufacturer’s instructions. Cytokine concentrations were calculated 
using Sector Image Reader (SI2400). Concentration of IFN- 2a was also mea-
sured using MSD technology. CXCL10 and IFN- were measured by ELISA 
(R&D Systems). Concentration levels were analyzed by two-way ANOVA.
In vitro stimulation of PBMCs with poly IC. PBMCs were isolated from 
blood of healthy donors via density gradient centrifugation. 106 freshly isolated 
PBMCs were pretreated with 10 µg/ml anti-IFNAR mAb (Fitzgerald Indus-
tries) or control-IgG (mouse IgG2a; BioLegend) for 1 h in 96-well round bot-
tom plates and subsequently stimulated with poly IC at 50 µg/ml (InvivoGen) 
or left unstimulated. Cells were harvested 13 h later and preserved in RLT 
buffer (QIAGEN) for future RNA extraction and microarray analyses.
Online supplemental material. Fig. S1 shows a flow diagram of clini-
cal trial design. Fig. S2 shows plots of 2D classical MDS and the first two 
PCAs to demonstrate that gene regulation was homogenous and peaked 
early on after s.c. poly ICLC. Fig. S3 shows the correlation of gene ex-
pression changes after poly ICLC by microarray and OpenArray PCR for 
selected genes. Table S1 shows demographic information of study volun-
teers. Table S2 lists DEGs 1 d after s.c. administration of poly ICLC in 
comparison to placebo. Table S3 lists IRGs. Table S4 shows the canonical 
pathways significantly regulated at 1 d after poly ICLC s.c. Table S5 lists 
the top commonly regulated genes in whole blood 1 d after poly ICLC 
s.c. and after in vitro stimulation of PBMCs with poly IC. Table S6 shows 
selected pathways and their genes commonly modulated after poly ICLC 
and YF17D. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20111171/DC1.
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